Statin-associated muscle symptoms

Reports of muscle pain, stiffness, or weakness in patients on HMG-CoA reductase inhibitors. True statin-associated myalgia occurs in 1–5% of patients in RCTs and up to 15% in observational studies. Approaches include switching molecule, dose reduction, and intermittent dosing.

ICD-10 M62.81 drug

Also known as: Statin-associated muscle symptoms (SAMS)

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

CUbidecarenone (coenzyme Q10)Not recommended · Other cardiac preparations. Coenzyme Q10Coenzyme Q10 is widely used as an «antidote» to statin myalgia based on the theory of CoQ10 depletion during statin therapy. Evidence is conflicting. Banach 2015 meta-analysis (12 RCTs, n=575) showed significant muscle pain score reduction. Later and larger Taylor 2015 (5 RCTs, n=253) and Qu 2018 (12 RCTs) analyses did not confirm the effect. ESC/EAS 2019 and AHA/ACC 2018 guidelines do not recommend CoQ10 as evidence-based therapy for statin myalgia; the supplement is permissible as an «option when statin switch is contraindicated» but not first-line. First-line management of statin myalgia: dose reduction, statin switch (pravastatin, fluvastatin), alternate-day dosing.

How to read tiers A–F

Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit